Looking Back at CAR T: PROs From a Patient's Perspective

A survivor of chronic lymphocytic leukemia who participated in the first chimeric antigen receptor T-cell trial in 2010 looks back at his experience and also discusses his views on how patient-reported outcomes (PROs) should be used, if at all, by CMS.

There are 2 approved chimeric antigen receptor (CAR) T-cell therapies on the market for patients with advanced leukemias and lymphomas, Novartis’ tisagenlecleucel (Kymriah) and Kite Pharma/Gilead’s axicabtagene ciloleucel (Yescarta). These immunotherapies are revolutionizing cancer treatment, albeit at great cost.

Doug Olson, a survivor of chronic lymphocytic leukemia, participated in the first CAR T trial in 2010, and joined a recent meeting of the Medicare Evidence Development and Coverage Advisory Committee convened by CMS to discuss how patient-reported outcomes (PROs) should be used, if at all, in any future coverage decisions.

He discussed his experience with CAR T, and his thoughts about PROs and costs, in a podcast after the meeting.

You may need to login to listen to the podcast.

iTunes: http://apple.co/2eYWTss

TuneIn: http://bit.ly/2gv7iwj

Stitcher: http://bit.ly/2gCqtFg

Listen above or through one of these podcast services:

MEDCAC Panel Mostly Endorses PROs for CAR T Therapies

Many Questions to Ask in Setting National Coverage for CAR T Therapies

NCCN Report on CAR T-Cell Therapy, Recommendations for Future Use

With Approval of CAR T-Cell Therapy Comes the Next Challenge: Payer Coverage

Learn more about CAR T:

Related Videos
Jennifer Kwon, PhD, on Reducing LDL Cholesterol in NHPs With Epigenome Editing
Olivier Danos, PhD, on Refining and Specifying AAV Gene Therapy
Paul Harmatz, MD, on Reducing GAGs in MPS Type 2 With RGX-121 Gene Therapy
Francesca Barone, MD, PhD, on Positive Biomarker, Overall Survival Data With CAN-3110 in High-Grade Glioma
Sung-Yun Pai, MD, on High T-Cell Reconstitution in X-SCID With Lentiviral Gene Therapy
Related Content
© 2023 MJH Life Sciences

All rights reserved.